Fraser Cara K, Diener Kerrilyn R, Brown Michael P, Hayball John D
Experimental Therapeutics Laboratory, Hanson Institute, and School of Pharmacy and Medical Sciences, Sansom Institute, University of South Australia, Australia.
Expert Rev Vaccines. 2007 Aug;6(4):559-78. doi: 10.1586/14760584.6.4.559.
While vaccination continues to be the most successful interventionist health policy to date, infectious disease remains a significant cause of death worldwide. A primary reason that vaccination is not able to generate effective immunity is a lack of appropriate adjuvants capable of initiating the desired immune response. Adjuvant combinations can potentially overcome this problem; however, the possible permutations to consider, which include the route and kinetics of vaccination, as well as combinations of adjuvants, are practically limitless. This review aims to summarize the current understanding of adjuvants and related immunological processes and how this knowledge can and has been applied to the strategic selection of adjuvant combinations as components of vaccines against human infectious disease.
尽管疫苗接种仍是迄今为止最成功的干预性卫生政策，但传染病仍是全球死亡的重要原因。疫苗接种无法产生有效免疫力的一个主要原因是缺乏能够引发所需免疫反应的合适佐剂。佐剂组合有可能克服这一问题；然而，需要考虑的可能组合实际上是无限的，这包括疫苗接种的途径和动力学，以及佐剂的组合。本综述旨在总结目前对佐剂及相关免疫过程的理解，以及这些知识如何能够并已经应用于佐剂组合的战略选择，作为针对人类传染病疫苗的组成部分。
